UBS AM’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$323K Buy
165,037
+61,736
+60% +$145K ﹤0.01% 2643
2025
Q4
$280K Sell
103,301
-23,069
-18% -$75.7K ﹤0.01% 2425
2025
Q3
$535K Sell
126,370
-99,902
-44% -$439K ﹤0.01% 2151
2025
Q2
$1.13M Buy
226,272
+86,023
+61% +$374K ﹤0.01% 2362
2025
Q1
$618K Sell
140,249
-9,696
-6% -$45.5K ﹤0.01% 2452
2024
Q4
$697K Buy
149,945
+61,924
+70% +$340K ﹤0.01% 2480
2024
Q3
$611K Sell
88,021
-85,926
-49% -$674K ﹤0.01% 2588
2024
Q2
$1.36M Buy
173,947
+122,381
+237% +$906K ﹤0.01% 2206
2024
Q1
$366K Buy
51,566
+9,250
+22% +$61.2K ﹤0.01% 2362
2023
Q4
$284K Sell
42,316
-971
-2% -$5.47K ﹤0.01% 2431
2023
Q3
$244K Buy
43,287
+19,810
+84% +$132K ﹤0.01% 2472
2023
Q2
$147K Hold
23,477
﹤0.01% 2605
2023
Q1
$147K Buy
23,477
+971
+4% +$5.41K ﹤0.01% 2605
2022
Q4
$105K Hold
22,506
﹤0.01% 2493
2022
Q3
$105K Buy
22,506
+5,706
+34% +$36K ﹤0.01% 2681
2022
Q2
$99.5K Buy
+16,800
New +$187K ﹤0.01% 2649
2021
Q2
Sell
-6,619
Closed -$258K 2764
2021
Q1
$258K Hold
6,619
﹤0.01% 2514
2020
Q4
$267K Buy
+6,619
New +$304K ﹤0.01% 2438

Other funds holding GDRX

UBS AM's GDRX Position: Q1 2026 in Review

UBS AM increased its GoodRx Holdings (GDRX) stake by 60% in Q1 2026, buying an estimated $145K and bringing the position to 165,037 shares worth $323K. The position accounts for ﹤0.01% of the portfolio, ranked #2643.

UBS AM first reported a position in GDRX in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.36M in Q2 2024. 174 funds tracked by Wall St. Rank hold GDRX as of Q1 2026.

  • UBS AM held 165,037 shares of GoodRx Holdings worth $323K as of Q1 2026.
  • UBS AM bought 61,736 GoodRx Holdings shares in Q1 2026, an estimated $145K.
  • GoodRx Holdings made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2643 holding.
  • UBS AM first reported a position in GoodRx Holdings in Q4 2020 and has held it in 18 quarters since.
  • UBS AM's GoodRx Holdings position peaked at $1.36M in Q2 2024.
  • 174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.